Recent News

• 01.13.2026 - argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG
• 01.12.2026 - argenx Highlights 2026 Strategic Priorities
• 01.06.2026 - argenx to Present at 44th Annual J.P. Morgan Healthcare Conference
• 01.05.2026 - argenx Announces Leadership Transition Marking Next Evolution of Growth
• 12.15.2025 - argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease
• 11.18.2025 - argenx Announces Results of Extraordinary General Meeting of Shareholders
• 10.30.2025 - argenx Reports Third Quarter 2025 Financial Results and Provides Business Update
• 10.29.2025 - argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients

Recent Filings

• 01.05.2026 - EX-99.1 EX-99.1
• 01.05.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 12.17.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 12.15.2025 - EX-99.1 EX-99.1
• 12.15.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.18.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.18.2025 - EX-99.1 EX-99.1
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 10.30.2025 - EX-99.1 EX-99.1
• 10.30.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]